The preoperative routine measurement of basal serum thyrocalcitonin (CT) in candidates for thyroidectomy due to thyroid nodules is currently a subject of debate.
M
edullary thyroid carcinoma (MTC) is an uncommon cancer that results from the neoplastic transformation of the parafollicular C cells of the thyroid gland. MTC is primarily sporadic but also arises in the context of a genetic pathology called multiple endocrine neoplasia type 2. MTC is a differentiated thyroid tumor that maintains the secreting function of C cells, i.e. the production of thyrocalcitonin (CT). This small polypeptide hormone is used as a tumor marker for MTC, which is suspected in cases of elevated basal serum CT levels. In patients with nodular thyroid, the measurement of basal serum CT levels has been proposed as a systematic screening method for MTC because its prevalence is about 1% in this population. However, this screening, which is recommended by the European Thyroid Association, has remained controversial for decades (1, 2) . Proponents of the screening find that it allows for an earlier diagnosis of MTC and adapted surgical procedures that finally improve the cure and prognosis of patients (3, 4) . For detractors, this screening is not cost effective, mainly because the incidence of MTC is too low in the nodular thyroid population and because basal serum CT is not sufficiently MTC specific (5) . Indeed, benign C cell hyperplasia (CCH) represents the most frequent cause of CT elevation. The pentagastrin (PG) test has been widely used to improve the specificity of CT as a tumor marker but this method also lacks specificity and is in any case no longer feasible due to the recent worldwide halt in PG commercialization. Throughout this long debate on the relevance of CT measurement as a screening method of MTC in the work-up of nodular thyroid disease, some practical issues of major importance for surgeons have been poorly addressed so far. First, should surgeons carry out a routine preoperative basal serum CT measurement before the surgical procedure, when a thyroidectomy is already proposed because of nodular thyroid disease? Second, as concerns preoperative hypercalcitoninemia, how should surgical and histopathological procedures be adapted and for which CT values? Finally, it is unclear how the recent unavailability of the PG test modifies these issues.
The aim of this study was to address these issues by reporting our experience with 2733 consecutive routine preoperative basal serum CT measurements and PG stimulation tests for the detection of MTC in a patient population undergoing thyroidectomy for nodular disorders regardless of preoperative CT values (i.e. in this study, CT levels are not used to screen patients for surgery).
Patients and Methods

Patients
We included 2733 consecutive patients referred for surgical treatment of nodular thyroid disorders between January 2000 and May 2009 (639 men and 2094 women) in two different institutions. In all patients, thyroid surgery was motivated by at least one of the following criteria: large nodular goiters with compression symptoms; nodules with malignant features at clinical examination, ultrasonography, or fine-needle aspiration biopsy (FNAB), toxic nodular goiter. Because the objective of our study was to test CT levels as a predictive factor of MCT, CT levels were not used to screen patients for surgery; this would create a significant source of bias in the study. Our patient population requires surgery for nodular disorders, regardless of preoperative CT levels. CT results were obtained after the decision of surgery was taken. Calcitonin elevation alone was not a motive for thyroidectomy. No patient had a family history of MTC or multiple endocrine neoplasia type 2.
Methods
Preoperative work-up
Minimal preoperative initial work-up systematically included: basal serum CT measurement under appropriate conditions (6); thyroid and cervical ultrasonography; measurement of circulating levels of free thyroid hormone and TSH; and titers of thyroperoxidase and thyroglobulin autoantibodies.
Serum CT protocol
Serum CT levels were determined a maximum of 1 month before the surgical procedure with a commercially available immunoradiometric assay (ELISA-hCT; CIS Biointernational, Gifsur-Yvette, France). A basal serum CT level less than 10 pg/ml was considered normal (7) . For patients with preoperative hypercalcitoninemia, the postoperative basal serum CT level was remeasured at least 6 wk after surgery.
PG stimulation test protocol
In patients with a basal serum CT level of 10 pg/ml or greater confirmed by a second test, we carried out a PG stimulation test combined with the measurement of plasma metanephrin to screen for pheochromocytoma. We also measured intact PTH (1-84) and calcium levels to screen for primary hyperparathyroidism. For PG tests, serum CT levels were measured before and 3 and 5 min after an iv injection of 0.5 g/kg PG (Peptavlon; Zeneca Pharma, Cergy, France). The PG test was considered abnormal when the serum CT peak was greater than 30 pg/ml according to the Groupe Français d'Etude des Tumeurs Endocrines recommendations (8) .
Molecular genetic analysis
We searched for the familial forms of MTC in all MTC patients by analyzing germline mutations of the ret protooncogene at exons 8, 10, 11, 13, 14, 15, and 16 on chromosome 10.
Surgical procedures and histopathological examination
All candidates for surgery (due to nodular thyroid disorders) required either partial or total thyroidectomy, regardless of their CT level. However, if their basal CT level was 10 pg/ml or greater, total thyroidectomy was opted for. In these cases the thyroid specimen was systematically sent intraoperatively for a histopathological analysis. Transversal serial sections (every 2 mm) were performed through the whole gland. Macroscopically suspect lesions were analyzed under microscope intraoperatively after a standard hematoxylin-eosin staining procedure. When an intraoperative diagnosis of MTC was made, a neck dissection of the central compartment (level VI) and a modified radical neck dissection (levels II-IV) were carried out as classically recommended (9 -11). After surgery, definitive histopathological analysis of the thyroid was performed, including an immunohistochemical examination using an anticalcitonin monoclonal antibody (anti-CT clone SP17; Roche Diagnostics, Mannheim, Germany) and a red Congo coloration to detect either CCH or microscopic MTC foci. CCH was quantitatively defined as a minimum of 50 C cells in three low-power fields (ϫ40) or miscroscopic foci containing more than six or 10 C cells per micronodule/field (12) .
Results
Preoperative basal serum CT levels
Preoperative basal serum CT levels were normal (Ͻ10 pg/ml) in 2690 patients (98.4%). They were elevated in 43 patients (1.6%), including 25 males and 18 females with a mean age of 55 yr (28 -83 yr). As presented in Table 1 , elevated basal serum CT levels ranged from 12 to 13.000 pg/ml (median 20 pg/ml; SD 2176 pg/ml).
Histopathology results
In our population of 2733 operated patients, definitive pathological examination identified 14 cases of sporadic MTC (0.5%), no cases of familial MTC, 33 cases of CCH TABLE 1. Basal CT levels, stimulated CT levels, histological findings, and characteristics of MTC in the 43 patients referred for surgical treatment of nodular thyroid diseases and for whom preoperative basal serum CT levels were greater than 10 pg/ml (1.2%), and 225 differentiated carcinomas (8.3%). In this cohort, MTC represented 6.2% of thyroid malignancies.
Correlation between preoperative basal serum CT levels and histopathology
Basal serum CT levels less than 10 pg/ml and diagnosis of MTC In the pool of 2690 patients with basal CT levels less than 10pg/ml, two cases of unifocal micro-MTC of 1 and 4 mm, respectively, were detected by definitive histopathological examination of the total thyroidectomy surgical specimen. These two micro-MTCs were not detected by preoperative ultrasonography.
Basal serum CT level of 10 pg/ml or greater and diagnostic of MTC Among the 43 patients with preoperative CT levels of 10 pg/ml or greater, we found 12 cases of MTC (26%) including five microcarcinomas (mean diameters 4.3 mm; minimum 1.5 mm; maximum 6 mm) and seven macrocarcinomas (mean diameters 25 mm; minimum 11 mm; maximum 39 mm). The seven macro-MTCs, whose size was greater than 11 mm, were suspected to be malignant on preoperative ultrasonography. Two of these suspect nodules were further explored by FNAB, which confirmed the MTC diagnosis. The five micro-MTCs were not suspected to be malignant on preoperative ultrasonography. No FNAB was carried out on nodules less than10 mm. The median basal serum CT level for macro-MTC was 1,900 pg/ml (206 -13,000 pg/ml), in contrast with 17 pg/ml (12-85 pg/ml) for micro-MTC. Nine of 12 MTCs (75%) were diagnosed intraoperatively by a comprehensive histopathological procedure. Among the 12 cases of MTC, nine were identified in the group of 18 females with a preoperative basal CT level of 10 pg/ml or greater (50%) and three in the group of 25 males with a preoperative basal CT level of 10 pg/ml or greater (12%). As concerns patients with preoperative hypercalcitoninemia, the risk of MTC was statistically higher in the female group (P ϭ 0.006; 2 test).
Basal serum CT levels of 10 pg/ml or greater and diagnosis of CCH CCH was found in 33 of the 43 patients with preoperative hypercalcitoninemia (76%). In two cases, it was associated with MTC. When CCH was found alone, the median basal serum CT level was 20 pg/ml (12-59 pg/ml).
Correlation between PG-stimulated CT levels and histopathological results
A PG stimulation test was carried out in 31 of the 43 patients with preoperative basal CT levels of 10 pg/ml or greater. In five patients with high basal CT elevation (85, 600, 1,900, 4,419, and 13,000 pg/ml), the preoperative PG test was considered useless and was avoided. Because PG was not available in our institution after June 2008, the last seven patients with preoperative hypercalcitoninemia did not have a PG test.
The PG-stimulated CT peak was 30 pg/ml or greater in all 31 cases and ranged from 38 to 14,000 pg/ml (median 100 pg/ml; SD 2,785 pg/ml). The PG stimulated CT level ranged up to 7,510 and 14,000 pg/ml in the two cases of macro-MTC and up to 53 pg/ml in the case of micro-MTC. In the 27 cases of CCH, the median value of stimulated CT was 80 pg/ml (38 -450 pg/ml). In one case, despite an elevation of both the basal serum CT level to 13 pg/ml and a PG-stimulated CT level of 203 pg/ml, no evidence of CCH or MTC was found.
Postoperative basal serum CT level
Basal serum CT levels fell down to normal values after surgery (CT Ͻ10 pg/ml) in all patients with CCH, micro-MTC and macro-MTC without lymph node involvement. Two patients with macro-MTC and lymph node metastasis had persistent hypercalcitoninemia despite an extensive initial surgical treatment (total thyroidectomy, central and bilateral cervical lymph node dissection).
Discussion
What are the advantages of routine preoperative basal serum CT measurement?
As previously suggested by Niccolli et al., we found that routine preoperative basal serum CT measurement in patients already selected for surgery is useful for several reasons (13) .
The first reason is because when CT dosage is followed by total thyroidectomy with comprehensive intraoperative histopathological analysis in the case of hypercalcitoninemia, it increases the rate of intraoperative MTC diagnosis (13). In our cohort, among 12 patients with MTC and basal CT level of 10pg/ml or greater, five patients had intraoperative diagnosis of latent subclinical micro-MTC, which would have been unlikely without previous knowledge of hypercalcitoninemia and subsequent comprehensive surgical procedure and pathological analysis. These micro-MTCs would have probably escaped other preoperative screening procedures, such as FNAB, which have proven to be inadequate for the diagnosis of small MTC lesions (14, 15) .
The second reason is because the intraoperative diagnosis of MTC enables the surgeon to immediately adapt the initial surgical treatment. In our study, patients with intraoperative diagnosis of MTC were able to benefit from a complete adapted initial surgical procedure by total thyroidectomy and neck dissection as classically recommended (11, 16, 17) . In one patient with subclinical latent micro-MTC, we found a metastatic lymph nodes in the central compartment, which would have never been treated properly without preoperative knowledge of hypercalcitoninemia and subsequent intraoperative MTC diagnosis. In three patients with unilateral suspect nodules scheduled for partial thyroidectomy, the fact that we opted for a total procedure due to elevated preoperative CT levels avoided a second procedure, as classically recommended (16) .
The third reason is because in the case of preoperative hypercalcitoninemia, even micronodules must be considered at risk of MTC and systematic total thyroidectomy is recommended when a surgical treatment is proposed. In our cohort, three cases of MTC were micronodules located on the opposite lobe of the nodules that motivated surgery. In these cases in which simple lobectomy would have been proposed, MTC diagnosis was finally made because we systematically chose total thyroidectomy when preoperative CT levels were greater than 10 pg/ml. In these three cases, MTC diagnosis on the contralateral lobe would have certainly been delayed without the help of preoperative CT dosage.
What are the limits of routine preoperative basal serum CT measurement?
Some authors consider that routine preoperative basal serum CT measurement results in overtreatment. In our cohort, routine measurement of serum CT levels lead to total thyroidectomy (instead of partial) in 12 patients with a final diagnosis of benign CCH and unilateral nodules. If one can consider that these patients were overtreated because they could have been treated by lobectomy, one can also consider that in the long term, most of them would undergo a contralateral surgical procedure due to the natural evolution of their nodular thyroid disease. From this point of view, a total thyroidectomy is not unreasonable.
Some authors consider that routine preoperative basal serum CT measurement is not cost effective. Considering a mean price of 23 Euros for CT measurement, the cost of systematic basal serum CT measurement was approximately 5240 Euros for the detection of one MTC in our study. Considering that all the macro-MTCs in our study were or could have been detected by other techniques, such as ultrasonography, FNAB, or intraoperative histopathological analysis, CT measurement enabled the detection of only five subclinical latent MTCs. Therefore, 12,570 Euros were necessary to detect one truly unsuspected MTC. Some authors consider that this cost is too high, especially when you consider that the evolution of these latent subclinical MTCs is still not clear. On the other hand, other authors suggest that the cost of serum CT measurement, even if added with the cost of the unnecessary total thyroidectomies (instead of lobectomies), would be considerably lower than the cost of a single MTC treatment failure due to later diagnosis or inappropriate initial surgical procedure in the absence of preoperative CT dosage (4, 18, 19) .
How to interpret preoperative basal serum CT values?
As reported in other studies, we confirmed that defining a normal basal serum CT value as less than 10 pg/ml provides an extremely sensitive method for preoperative screening of MTC in the nodular thyroid population (4, 13, (22) (23) (24) . In our cohort of 2690 patients with basal serum CT levels less than 10 pg/ml, we observed only two cases of micro-MCTs and no macro-MTCs. In this study, the sensitivity of this test was 100% for macro-MTC screening and 99.3% for micro-MTC. Recently Rink et al. (25) suggested that the threshold for normal CT levels be raised to 15 pg/ml to decrease the number of false positives for this test (hypercalcitoninemia without MTC). If we had used this cutoff in our cohort of 2733 patients, 12 of 43 (28%) would have been excluded from our hypercalcitoninemia protocol, and consequently, one diagnosis of micro-MTC would have been missed. We think that the commonly admitted normal CT cutoff of less than 10 pg/ml must be used because it favors sensitivity that is necessary to improve early diagnosis.
In our study, MTC was always present when the basal serum CT level was greater than 60 pg/ml. Other authors found different cutoff values, which they consider pathognomonic for MTC, ranging from 36 pg/ml for Iacobone et al. (18) to 64 pg/ml for Scheuba et al. (22) . Based on these results and considering the fact that specificity should be favored when defining pathognomonic cutoffs, we consider that basal serum CT level is pathognomonic for MTC when greater than 60 pg/ml. When such elevated CT values are detected, we recommend the following measures: a preoperative evaluation of the lymph nodes of the neck by precise cervical imaging, a complete surgical procedure with total thyroidectomy, an intraoperative comprehensive histopathological analysis, and a neck dissection of at least level VI.
We found that when the preoperative basal serum CT level was between 10 and 59 pg/ml, diagnosis of CCH was more frequent (89% of CCH vs. 11% of MTC). This range of CT values represents a gray zone in which it is not possible to determine whether hypercalcitoninemia is due to the presence of MTC or CCH (26) . Consequently, we recommend total thyroidectomy with intraoperative comprehensive histopathological analysis. Central lymph node dissection is carried out only if MTC is present. It is also worth mentioning that in the case of hypercalcitoninemia, MTC is statistically more frequent in women than in men (50 vs. 11% in our cohort; P ϭ 0.006; 2 test).
This result, consistent with a previous report by Iacobone et al. (18) , suggests that particular concern should be given to women with preoperative hypercalcitoninemia.
What was the impact of preoperative PG test for MTC diagnostic?
Until recently the PG test has been used to improve CT specificity as an MTC tumor marker in patients with hypercalcitoninemia. In this study we found that the PG test was actually of little interest in this indication. In our experience with abnormal stimulated CT values between 30 and 450 pg/ml, even if CCH was definitely more frequent, MTC could not be excluded because we found one case of micro-MTC with a stimulated CT value of 53 pg/ml. Among these patients, six with a diagnosis of CCH had stimulated CT values greater than 200 pg/ml (206 -450 pg/ml). These data are worth mentioning because it is not in accordance with the findings of other authors who considered that stimulated CT values greater than 200 pg/ml are highly predictive of MTC (18) . In our experience, this pathognomonic cutoff is 450 pg/ml because above this value, we found two patients with macro-MTC and no CCH. Unfortunately, this cutoff has no additional diagnostic value because these two patients both had basal serum CT levels greater than 60 pg/ml, which, as we previously mentioned, is by itself pathognomonic of MTC.
The PG test has also been proposed as a way to distinguish so-called true hypercalcitoninemia due to thyroid C cell pathologies (CCH or MTC) from hypercalcitoninemia of extrathyroidal origin (6) . We believe that this function attributed to the PG test is not relevant, mainly because the incidence of normal stimulated PG with elevated basal serum CT level (supposed to be characteristic extrathyroidal hypercalitoninemia) is extremely rare [none of 43 patients in our experience and one of 45 patients for Elisei et al. (4) ]. Consequently, very few of the patients subjected to this costly and uncomfortable test would actually benefit from it.
In the preoperative context, we consider that the PG test was a rather expensive procedure, sometimes associated with significant side effects and with a specificity too limited to guide the surgical management of patients with hypercalcitoninemia. Its disappearance is therefore not a concern in this setting. On the other hand, this disappearance is definitely more problematic in the follow-up of patients with an MTC diagnosis, in which it helped to detect early recurrences of the disease.
Conclusion
This study raises the question of whether the preoperative measurement of serum CT levels should be carried out routinely for patients with nodular disorders already selected for thyroidectomy (i.e. in which CT levels were not used to screen patients for surgery).
In our experience, this systematic measurement associated with total thyroidectomy and comprehensive histopathological analysis improves MTC management. In a cohort of 2733 patients, it largely contributed to the early diagnosis and adapted surgical treatment of five MTCs. Without the use of this procedure, MTC diagnosis would have been delayed in three cases, surgical procedures would have been incomplete at the thyroid level in three cases, and at the lymph node level in one case. The main drawbacks of this procedure are limited to the cost of negative tests (numerous but not expensive) and the cost of unnecessary total thyroidectomies (expensive but rare). Considering the medicoeconomic and ethical implications of either delayed diagnosis or inappropriate initial surgical procedures in patients with MTC, we recommend carrying out a routine preoperative measurement of basal serum CT in thyroidectomy candidates with nodular thyroid disease.
As concerns preoperative hypercalcitoninemia between 10 and 59 pg/ml, MTC must be actively searched for. In this case, a prudent course of action requires total thyroidectomy with comprehensive preoperative histopathological analysis to optimize lesion detection. A basal serum CT of 60 pg/ml or greater should be considered pathognomonic for MTC.
